Emylif: Uses, Dosage & Side Effects
Riluzole orodispersible film for the treatment of amyotrophic lateral sclerosis (ALS) in adults – dissolves on the tongue without water
Emylif is a prescription medication containing riluzole in an orodispersible film formulation, designed for the treatment of amyotrophic lateral sclerosis (ALS) in adults. ALS, also known as motor neurone disease (MND) or Lou Gehrig’s disease, is a progressive neurodegenerative condition that affects the motor neurons controlling voluntary muscle movement. Riluzole is the first and, for many years, the only drug shown to extend survival in ALS patients. The Emylif orodispersible film dissolves on the tongue within approximately 3 minutes, requiring no water, tongue mobility, or muscular strength – making it particularly suitable for patients experiencing dysphagia (difficulty swallowing), a common and often debilitating symptom of ALS.
Quick Facts: Emylif
Key Takeaways
- Emylif contains riluzole, the first drug proven to extend survival in amyotrophic lateral sclerosis (ALS), extending median survival by approximately 2–3 months when started early in the disease course.
- The orodispersible film formulation dissolves on the tongue within approximately 3 minutes without needing water, making it ideal for ALS patients with swallowing difficulties (dysphagia).
- Riluzole works by reducing glutamate-mediated excitotoxicity, which is believed to be a key contributor to motor neuron degeneration in ALS, though it does not cure the disease or reverse existing damage.
- Regular liver function monitoring is essential: serum ALT should be checked before treatment, monthly for the first 3 months, quarterly for the remainder of the first year, and periodically thereafter, as hepatotoxicity is a known risk.
- The standard dosage is one 50 mg film twice daily (100 mg/day), taken 12 hours apart on an empty stomach; the most common side effects include nausea, asthenia (weakness), and transient oral hypoaesthesia (numbness in the mouth).
What Is Emylif and What Is It Used For?
Emylif contains the active substance riluzole, a benzothiazole derivative that belongs to the class of glutamate antagonists. It is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adult patients. ALS is a devastating, progressive neurodegenerative disease that selectively destroys upper and lower motor neurons in the brain and spinal cord, leading to progressive muscle weakness, wasting (atrophy), spasticity, and eventually paralysis. The disease affects approximately 2–5 per 100,000 people worldwide, with a median survival of 3–5 years from symptom onset. ALS is also known by several other names, including motor neurone disease (MND), Lou Gehrig’s disease (in the United States), and Charcot’s disease (in France).
The pathophysiology of ALS involves multiple interconnected mechanisms, but one of the most well-established is glutamate-mediated excitotoxicity. Glutamate is the principal excitatory neurotransmitter in the central nervous system. Under normal conditions, glutamate is released by neurons during synaptic transmission and rapidly cleared from the synaptic cleft by specialized transporter proteins on surrounding astrocytes. In ALS, this clearance mechanism is impaired, resulting in excessive accumulation of glutamate in the extracellular space. The persistent overstimulation of glutamate receptors on motor neurons (particularly NMDA and kainate receptors) triggers a cascade of intracellular events including excessive calcium influx, mitochondrial dysfunction, oxidative stress, and ultimately neuronal death. This process is known as excitotoxicity, and it is a major driver of the progressive motor neuron degeneration seen in ALS.
Riluzole was developed specifically to counteract this excitotoxic process. Its mechanism of action is multifaceted and involves several distinct pharmacological effects. First, riluzole inhibits the presynaptic release of glutamate from nerve terminals, thereby reducing the amount of glutamate available to overstimulate motor neurons. Second, riluzole inactivates voltage-dependent sodium channels, with a particular preference for tetrodotoxin (TTX)-sensitive sodium channels that are associated with damaged or depolarized neurons. By blocking these channels, riluzole reduces the excessive neuronal firing that drives glutamate release in pathological conditions. Third, riluzole has been shown to interfere with intracellular signaling events downstream of glutamate receptor activation, including inhibition of kainate and NMDA receptor-mediated responses. Together, these mechanisms provide a neuroprotective effect by reducing the excitotoxic burden on vulnerable motor neurons.
The clinical efficacy of riluzole in ALS was established in two landmark randomized, double-blind, placebo-controlled trials. The first trial, published by Bensimon et al. in 1994 in the New England Journal of Medicine, enrolled 155 patients with ALS and demonstrated that riluzole 100 mg/day significantly improved survival at 12 months compared with placebo (74% vs. 58%, p = 0.014). The second, larger confirmatory trial (Lacomblez et al., 1996, The Lancet) enrolled 959 patients and confirmed that riluzole 100 mg/day extended median survival by approximately 2–3 months. A subsequent dose-ranging analysis established that the 100 mg daily dose (50 mg twice daily) offered the optimal balance between efficacy and tolerability. These findings have been further supported by meta-analyses and real-world evidence studies, including a Cochrane systematic review that confirmed the survival benefit of riluzole in ALS.
It is important to understand that riluzole does not cure ALS and has not been shown to reverse existing motor neuron damage or improve motor function. However, it is the only drug consistently proven to extend survival in ALS, which is why international guidelines from organizations such as the European Federation of Neurological Societies (EFNS), the European Academy of Neurology (EAN), the American Academy of Neurology (AAN), and the National Institute for Health and Care Excellence (NICE) unanimously recommend riluzole as first-line disease-modifying treatment for ALS. Treatment should ideally be initiated as early as possible in the disease course, as riluzole has not been shown to be effective in the late stages of ALS.
Emylif represents an important advance in the delivery of riluzole therapy. Traditional riluzole formulations (film-coated tablets and oral suspension) require intact swallowing ability, which progressively deteriorates in many ALS patients. Dysphagia affects up to 80–85% of ALS patients during the course of their disease and can make taking conventional oral medications extremely difficult, distressing, or even dangerous due to the risk of aspiration. The Emylif orodispersible film is a thin, flexible strip that is placed on the top of the tongue, where it dissolves within approximately 3 minutes. It does not require water, tongue mobility, or significant muscular strength to administer, making it an invaluable formulation for patients experiencing swallowing difficulties. Bioequivalence studies have demonstrated that Emylif provides equivalent systemic exposure to riluzole compared with the standard film-coated tablet formulation.
Difficulty swallowing (dysphagia) is one of the most challenging symptoms of ALS, affecting the majority of patients as the disease progresses. Emylif’s orodispersible film format addresses this directly by eliminating the need for water or a swallowing motion. The film dissolves on the tongue, allowing the medication to be absorbed through the oral mucosa and gastrointestinal tract. This innovation helps ensure that patients can continue their riluzole treatment even as their swallowing function declines, which is critical for maintaining the survival benefit of the medication throughout the disease course.
What Should You Know Before Taking Emylif?
Contraindications
Emylif must not be used in certain situations due to the risk of serious harm. The following are absolute contraindications to riluzole therapy:
- Hypersensitivity: Do not use Emylif if you are allergic to riluzole or to any of the other ingredients in the formulation. Severe hypersensitivity reactions, including anaphylaxis and angioedema, have been reported in post-marketing experience, although such events are rare.
- Hepatic impairment: Riluzole is contraindicated in patients with baseline hepatic (liver) disease or those with baseline serum transaminase levels (ALT or AST) exceeding 3 times the upper limit of normal (ULN). Riluzole undergoes extensive hepatic metabolism and is a known hepatotoxin; administering it to patients with pre-existing liver dysfunction significantly increases the risk of severe hepatic injury.
- Pregnancy: Riluzole is contraindicated during pregnancy. Animal reproductive studies have demonstrated fetotoxicity and teratogenicity at doses near the human therapeutic dose. In the absence of adequate data from human pregnancies, the potential risk to the fetus is considered unacceptable.
- Breastfeeding: It is not known whether riluzole or its metabolites are excreted in human breast milk. Given the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during Emylif treatment.
Warnings and Precautions
Riluzole can cause liver damage, including rare fatal cases. Serum ALT levels should be measured before starting treatment, monthly for the first 3 months, every 3 months for the remainder of the first year, and periodically thereafter. Treatment should be discontinued if ALT exceeds 5 times the upper limit of normal. Patients should be advised to report any unexplained nausea, vomiting, abdominal pain, fatigue, dark urine, or yellowing of the skin or eyes (jaundice) immediately.
Liver function monitoring is the single most important safety measure when using Emylif. In clinical trials, approximately 50% of riluzole-treated patients experienced at least one elevation of serum alanine aminotransferase (ALT) above the upper limit of normal, and approximately 8% experienced elevations exceeding 3 times the ULN. Most elevations occurred within the first 3 months of treatment and were reversible upon dose reduction or discontinuation. However, cases of severe hepatic injury, including hepatitis, hepatic failure, and death, have been reported in post-marketing surveillance, underscoring the importance of strict adherence to the liver monitoring schedule.
Additional precautions include:
- Neutropenia: Riluzole can reduce the number of neutrophils (a type of white blood cell) in the blood, increasing the risk of infection. Blood counts should be performed if febrile illness develops during treatment. If the neutrophil count falls below 1,500 cells/mm³, treatment should be interrupted.
- Interstitial lung disease: Cases of interstitial lung disease, including hypersensitivity pneumonitis, have been reported in patients treated with riluzole. If symptoms such as dry cough or dyspnea develop, a chest radiograph should be obtained and riluzole discontinued if interstitial lung disease is confirmed.
- Renal impairment: There are limited data on the use of riluzole in patients with impaired kidney function. Caution is advised in these patients, and dose adjustment may be considered based on clinical response and tolerability.
Pregnancy and Breastfeeding
Emylif is contraindicated during pregnancy. Animal studies with riluzole have shown adverse effects on embryo-fetal development, including reduced fetal weight and increased incidence of skeletal variations, at doses that produce plasma levels similar to those in humans at therapeutic doses. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential should use effective contraception during treatment with Emylif and for at least one month after the last dose.
Breastfeeding is also contraindicated during Emylif treatment. It is not established whether riluzole or its metabolites pass into human breast milk. Given the potential for serious hepatic and hematologic adverse effects in the breastfed infant, a decision must be made to either discontinue breastfeeding or discontinue riluzole treatment, taking into account the importance of the drug to the mother.
Driving and Operating Machinery
Riluzole may cause dizziness and somnolence (drowsiness), which could impair the ability to drive or operate machinery. Patients should be cautioned about these potential effects and advised not to drive or use machines if they experience these symptoms. It is important to note that ALS itself progressively impairs motor function, which independently affects the ability to drive safely. The decision to continue driving should be made in consultation with your healthcare team, considering both the effects of the medication and the underlying disease.
How Does Emylif Interact with Other Drugs?
Understanding the drug interaction profile of riluzole is clinically important because its metabolism depends heavily on the cytochrome P450 enzyme CYP1A2. Unlike monoclonal antibodies that are degraded through general protein catabolism, riluzole is a small molecule that undergoes extensive hepatic first-pass metabolism, making it susceptible to interactions with other drugs that affect CYP1A2 activity. Approximately 60% of an oral dose of riluzole is absorbed, and it is then extensively metabolized by CYP1A2 (and to a lesser extent by CYP2D6, CYP2C19, CYP3A4, and CYP2E1) to several metabolites, of which the major one is N-hydroxyriluzole. The elimination half-life of riluzole is approximately 9–15 hours.
The following table summarizes the most clinically relevant drug interactions with riluzole:
| Drug / Substance | Interaction Type | Clinical Significance |
|---|---|---|
| Fluvoxamine | Strong CYP1A2 inhibitor – increases riluzole exposure | Major – avoid co-administration or use extreme caution |
| Ciprofloxacin | Moderate CYP1A2 inhibitor – increases riluzole levels | Major – consider alternative antibiotic |
| Enoxacin | Strong CYP1A2 inhibitor – increases riluzole exposure | Major – avoid co-administration |
| Smoking (tobacco) | CYP1A2 inducer – decreases riluzole levels by up to 50% | Moderate – monitor efficacy; dose adjustment may be needed |
| Rifampicin | CYP1A2/3A4 inducer – decreases riluzole levels | Moderate – monitor therapeutic response |
| Omeprazole | Mild CYP1A2 inducer – may decrease riluzole levels | Minor – generally not clinically significant |
| Charcoal-grilled foods | Dietary CYP1A2 inducer – may decrease riluzole levels | Minor – moderate intake is acceptable |
| Hepatotoxic drugs (allopurinol, methyldopa, sulfasalazine) | Additive hepatotoxicity risk | Moderate – increased liver monitoring required |
| Caffeine | CYP1A2 substrate – may compete for metabolism | Minor – moderate caffeine intake is acceptable |
Major Interactions
The most significant interaction is with fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) antidepressant that is also the most potent known clinical inhibitor of CYP1A2. Co-administration of fluvoxamine with riluzole can increase the area under the curve (AUC) of riluzole by approximately 5-fold and maximum plasma concentration (Cmax) by approximately 2-fold, substantially increasing the risk of dose-dependent adverse effects, particularly hepatotoxicity and nausea. This combination should be avoided whenever possible. If an antidepressant is required for an ALS patient (depression is common in ALS, affecting up to 30–40% of patients), alternative agents that do not significantly inhibit CYP1A2, such as sertraline or citalopram, should be considered.
Ciprofloxacin and other fluoroquinolone antibiotics are moderate inhibitors of CYP1A2 and can also increase riluzole exposure. When a course of ciprofloxacin is necessary, enhanced liver monitoring is recommended and alternative antibiotics without CYP1A2 inhibitory properties should be considered where clinically appropriate.
Minor Interactions
Cigarette smoking is a potent inducer of CYP1A2 and has been shown to reduce riluzole plasma concentrations by approximately 50%. Patients who smoke should be informed that smoking may decrease the effectiveness of their medication. Conversely, patients who stop smoking during treatment should be monitored for potential increases in riluzole levels and associated side effects. Other mild CYP1A2 inducers include omeprazole and charcoal-grilled foods, although these are generally not considered clinically significant at normal consumption levels.
Always inform your doctor, pharmacist, or specialist nurse about all medications you are taking, including over-the-counter drugs, herbal supplements, and dietary habits (particularly caffeine intake and smoking status). This information is essential for safe prescribing and monitoring of riluzole therapy.
What Is the Correct Dosage of Emylif?
Emylif should always be used exactly as prescribed by your doctor. The dosing of riluzole is straightforward and does not typically require individualized titration. However, adherence to the correct administration technique is particularly important for the orodispersible film formulation to ensure optimal drug delivery.
Adults
| Parameter | Recommendation |
|---|---|
| Single dose | 50 mg (one orodispersible film) |
| Frequency | Twice daily (every 12 hours) |
| Total daily dose | 100 mg |
| Timing | At least 1 hour before or 2 hours after a meal |
| Administration | Place on tongue; dissolves in approximately 3 minutes |
To administer Emylif correctly, follow these steps: Wash your hands thoroughly before handling the film. Open the sachet carefully along the perforation and gently remove the orodispersible film. Ensure your tongue is dry. Place the film on the top of your tongue and allow it to dissolve completely. Do not chew, crush, or break the film. Do not take the film with food or liquids. After the film has dissolved, saliva containing the dissolved medication can be swallowed normally. The film typically dissolves within approximately 3 minutes.
Food significantly affects the absorption of riluzole. Taking riluzole with a high-fat meal reduces the maximum plasma concentration (Cmax) by approximately 44% and the area under the curve (AUC) by approximately 17%. Therefore, Emylif should be taken on an empty stomach, at least 1 hour before or 2 hours after a meal, to ensure consistent and optimal absorption.
Children and Adolescents
Emylif is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of riluzole have not been established in the pediatric population. ALS is extremely rare in children and adolescents, and no clinical data exist to support the use of riluzole in this age group.
Elderly Patients
No dose adjustment is required for elderly patients based on age alone. The pharmacokinetic parameters of riluzole are not significantly altered in elderly individuals. However, elderly patients are more likely to have reduced hepatic and renal function, and they may be taking multiple concomitant medications. Therefore, careful monitoring of liver function and clinical response is advisable in older patients. The mean age of ALS onset is approximately 55–65 years, so many patients receiving riluzole are in this age group.
Missed Dose
If you miss a dose of Emylif, skip the missed dose and take the next dose at the regularly scheduled time. Do not take a double dose to make up for a missed one. Taking two doses too close together increases the risk of side effects, particularly nausea and hepatotoxicity. If you frequently forget to take your medication, discuss strategies with your healthcare team, such as setting alarm reminders or using a medication diary. Consistent twice-daily dosing is important for maintaining therapeutic riluzole levels in the bloodstream.
Overdose
Cases of riluzole overdose have been reported, including acute ingestion of doses up to 1,500–3,000 mg (15–30 times the recommended daily dose). Symptoms of overdose may include nausea, vomiting, somnolence, methemoglobinemia (a condition in which hemoglobin is converted to a form that cannot carry oxygen effectively, potentially causing cyanosis and shortness of breath), and neurological symptoms. There is no specific antidote for riluzole overdose. Management is supportive, including monitoring of vital signs, liver function, and blood counts. Methemoglobinemia may be treated with intravenous methylene blue if clinically significant. If you suspect an overdose, contact your local poison control center or seek emergency medical attention immediately.
What Are the Side Effects of Emylif?
Like all medicines, Emylif can cause side effects, although not everyone who takes it will experience them. The safety profile of riluzole has been well characterized through decades of clinical use since its initial approval in 1995. The most commonly reported adverse reactions in clinical trials were nausea, asthenia (weakness/fatigue), and elevated liver enzymes (ALT). The orodispersible film formulation has an additional common side effect of oral hypoaesthesia (numbness in the mouth), which is generally mild and transient.
Understanding the potential side effects of riluzole is important for patients and caregivers, as it helps distinguish medication-related effects from symptoms of the underlying ALS disease itself. Many symptoms of ALS (such as weakness, fatigue, breathing difficulties, and weight loss) overlap with potential side effects of riluzole, making careful clinical assessment essential.
Very Common
May affect more than 1 in 10 people
- Nausea
- Asthenia (weakness, fatigue)
- Elevated liver enzymes (ALT increase)
- Decreased lung function (reduced vital capacity)
Common
May affect up to 1 in 10 people
- Headache
- Dizziness
- Drowsiness (somnolence)
- Oral hypoaesthesia (mouth numbness – specific to orodispersible film)
- Oral paraesthesia (tingling in mouth)
- Vomiting
- Abdominal pain
- Diarrhea
- Tachycardia (fast heart rate)
Uncommon
May affect up to 1 in 100 people
- Interstitial lung disease (including hypersensitivity pneumonitis)
- Pancreatitis
- Anemia
Rare
May affect up to 1 in 1,000 people
- Neutropenia (low white blood cell count)
- Hepatitis (liver inflammation)
- Severe allergic reactions (angioedema, anaphylaxis)
Not Known
Frequency cannot be estimated from available data
- Hepatic failure (liver failure)
- Methemoglobinemia
- Renal tubular impairment
Nausea is the most frequently reported side effect and typically occurs during the first few weeks of treatment. It is usually mild to moderate in severity and often improves with continued use. Taking riluzole on an empty stomach (as directed) and avoiding lying down immediately after administration can help minimize nausea. Anti-emetic medications may be prescribed if nausea is persistent or troublesome.
Elevated liver enzymes (particularly ALT) are very common with riluzole therapy. Approximately 50% of patients will experience at least one ALT elevation above the upper limit of normal. Most elevations are mild (less than 3 times ULN) and occur within the first 3 months of treatment. In the majority of cases, ALT levels return to normal either spontaneously or after dose adjustment. However, approximately 2% of patients develop ALT elevations exceeding 5 times the ULN, which is the threshold for mandatory treatment discontinuation. Cases of severe hepatic injury, including hepatic failure with fatal outcome, have been reported in post-marketing surveillance, although these events are rare. Study data suggest that Asian patients may be more susceptible to liver function test abnormalities.
Oral hypoaesthesia (numbness in the mouth) is a side effect specific to the orodispersible film formulation and is related to the local effect of riluzole on the oral mucosa. It typically occurs immediately after film administration and resolves within approximately 40 minutes. This effect is generally considered mild and does not usually lead to treatment discontinuation.
Interstitial lung disease is an uncommon but potentially serious adverse effect. Cases of hypersensitivity pneumonitis and other forms of interstitial lung disease have been reported in patients receiving riluzole. Symptoms may include new or worsening cough, dyspnea (shortness of breath), and fever. Because ALS itself can cause respiratory muscle weakness and decreased lung function, any new respiratory symptoms should be carefully evaluated to distinguish medication-related effects from disease progression. If interstitial lung disease is confirmed, riluzole should be permanently discontinued.
Contact your doctor or seek emergency medical care immediately if you experience: unexplained nausea, vomiting, abdominal pain, or fatigue (possible liver injury); dark urine or yellowing of the skin or eyes (jaundice); fever, sore throat, or signs of infection (possible neutropenia); new or worsening cough, shortness of breath, or fever (possible interstitial lung disease); difficulty breathing, facial swelling, or severe skin rash (possible allergic reaction).
How Should You Store Emylif?
Proper storage of Emylif is essential to maintain the quality and effectiveness of the orodispersible film. The film is sensitive to moisture, which can affect its dissolution characteristics and drug stability. Adhering to the recommended storage conditions ensures that each dose delivers the intended amount of riluzole.
- Temperature: Store Emylif below 30 °C (86 °F). Do not refrigerate or freeze the orodispersible films, as extreme temperatures can alter the film’s physical properties and dissolution rate.
- Moisture protection: Keep the films in their original packaging (individually sealed sachets) until you are ready to use them. The sachets provide a moisture barrier that protects the orodispersible film from environmental humidity. Do not open a sachet until immediately before administration.
- Light protection: Store in the original outer carton to protect from light exposure, which can degrade riluzole over time.
- Keep out of reach of children: Store Emylif in a secure location where children cannot access it. Accidental ingestion by a child could be harmful.
- Expiration date: Do not use Emylif after the expiration date printed on the sachet and outer carton after “EXP.” The expiration date refers to the last day of the indicated month. Expired medication should be disposed of according to local pharmacy regulations.
- Handling: Handle the orodispersible film with dry hands only. Wet or moist fingers can cause the film to dissolve prematurely or stick together. If a film is damaged, discolored, or has been exposed to moisture, do not use it and take a replacement from a new sachet.
When traveling with Emylif, keep the medication in its original packaging and store it in a cool, dry place. Avoid leaving it in a hot car, in direct sunlight, or in humid environments such as bathrooms. If you are traveling by air, carry your medication in your hand luggage where temperature conditions are more controlled.
Dispose of unused or expired medications responsibly. Do not throw Emylif in household waste or flush it down the toilet. Return any unused medication to your pharmacy for safe disposal in accordance with local environmental regulations. This helps protect the environment from pharmaceutical contamination.
What Does Emylif Contain?
Understanding the full composition of your medication is important, particularly if you have known allergies, dietary restrictions, or sensitivities to specific pharmaceutical ingredients.
Active Ingredient
The active substance is riluzole (2-amino-6-trifluoromethoxybenzothiazole), a benzothiazole derivative with the molecular formula C8H5F3N2OS and a molecular weight of 234.2 g/mol. Each orodispersible film contains exactly 50 mg of riluzole. Riluzole is a white to slightly yellow powder that is practically insoluble in water, which is why it has been formulated into an orodispersible film rather than a conventional tablet that requires swallowing with water.
Inactive Ingredients (Excipients)
| Ingredient | Role | Notes |
|---|---|---|
| Riluzole | Active substance (glutamate antagonist) | 50 mg per film |
| Pullulan | Film-forming polymer | Creates the dissolvable film matrix |
| Glycerol | Plasticizer | Provides film flexibility |
| Xanthan gum | Thickening agent / stabilizer | Controls dissolution rate |
| Potassium acesulfame | Sweetener | Improves taste |
| Sucralose | Sweetener | Non-caloric sweetener |
| Peppermint flavor | Flavoring agent | Masks taste of active ingredient |
| Citric acid (anhydrous) | pH adjuster | Optimizes dissolution |
| Titanium dioxide (E171) | Opacifier / colorant | Gives the film its white appearance |
Appearance and Pack Sizes
Emylif orodispersible film is a white to off-white, rectangular film. Each film is individually sealed in a moisture-protective sachet. Emylif is available in pack sizes of 56 films (28-day supply at standard dosing of 2 films per day). Not all pack sizes may be marketed in every country. The films should be handled with dry hands and placed on the tongue immediately after opening the sachet.
Marketing Authorization and Manufacturer
Emylif is developed and marketed for the treatment of ALS in adults. Riluzole was first approved as Rilutek (film-coated tablets) by the FDA in 1995 and by the EMA in 1996, making it the first drug approved specifically for ALS. The orodispersible film formulation (Emylif) was subsequently developed to address the unmet need of ALS patients with dysphagia, receiving regulatory approval in the EU and UK. Other riluzole formulations available globally include Rilutek (film-coated tablets), Tiglutik (oral suspension), and Exservan (oral film, available in the US).
Frequently Asked Questions About Emylif
Emylif (riluzole) is a prescription medication used for the treatment of amyotrophic lateral sclerosis (ALS) in adults. ALS is a progressive neurodegenerative disease that affects motor neurons, leading to muscle weakness, paralysis, and eventually respiratory failure. Riluzole is the first and most established disease-modifying treatment for ALS, proven to extend survival by approximately 2–3 months. Emylif is formulated as an orodispersible film that dissolves on the tongue, making it suitable for patients with swallowing difficulties.
Both Emylif and Rilutek contain the same active ingredient (riluzole 50 mg) and are taken at the same dose (50 mg twice daily). The key difference is the formulation: Rilutek is a conventional film-coated tablet that must be swallowed whole with water, while Emylif is an orodispersible film that dissolves directly on the tongue without the need for water or swallowing ability. This is a significant advantage for ALS patients, as dysphagia (difficulty swallowing) affects up to 80–85% of patients during the disease course. Bioequivalence studies have confirmed that Emylif provides equivalent systemic exposure to riluzole compared with Rilutek tablets.
No, Emylif does not cure ALS and has not been shown to reverse existing motor neuron damage or improve motor function. Riluzole is a disease-modifying treatment that slows the progression of ALS by reducing glutamate-mediated excitotoxicity. Clinical trials have demonstrated that riluzole extends median survival by approximately 2–3 months and may delay the need for tracheostomy or mechanical ventilation. Treatment is most effective when started early in the disease course. While a 2–3 month survival benefit may seem modest, it is clinically meaningful in the context of a disease with a median survival of only 3–5 years and for which very few treatments are available.
Riluzole is metabolized extensively by the liver and is a known hepatotoxin. Approximately 50% of patients experience at least one elevated ALT level during treatment. While most elevations are mild and reversible, serious hepatic injury including liver failure and death has been reported in rare cases. Regular liver function tests allow your doctor to detect early signs of liver damage before they become clinically significant. The monitoring schedule is: before starting treatment, monthly for the first 3 months, every 3 months for the remainder of the first year, and periodically thereafter. If your ALT exceeds 5 times the upper limit of normal, riluzole must be discontinued.
No, Emylif should be taken on an empty stomach, at least 1 hour before or 2 hours after a meal. This is because food, particularly high-fat meals, significantly reduces the absorption of riluzole. A high-fat meal can decrease the peak plasma concentration by approximately 44%. Taking Emylif consistently on an empty stomach ensures optimal and predictable absorption of the medication. The orodispersible film should be placed on a dry tongue and allowed to dissolve completely without food or liquids.
Oral hypoaesthesia (mouth numbness) is a common and expected side effect specific to the orodispersible film formulation. It is caused by the local effect of riluzole on nerve endings in the oral mucosa and typically begins shortly after the film dissolves. The numbness is generally mild and resolves on its own within approximately 40 minutes. It does not indicate a systemic problem and is not harmful. If the sensation is bothersome, you may find it helpful to avoid eating or drinking hot beverages until the numbness subsides. This side effect is not a reason to discontinue treatment.
References
- European Medicines Agency (EMA). Emylif (riluzole) – Summary of Product Characteristics. Available at: EMC Emylif SmPC.
- U.S. Food and Drug Administration (FDA). Riluzole – Prescribing Information. Revised 2024.
- Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330(9):585–591. doi:10.1056/NEJM199403033300901.
- Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347(9013):1425–1431. doi:10.1016/S0140-6736(96)91680-3.
- Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;(3):CD001447. doi:10.1002/14651858.CD001447.pub3.
- National Institute for Health and Care Excellence (NICE). Motor neurone disease: assessment and management. NICE Guideline NG42. Updated 2024. Available at: NICE NG42.
- Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) – revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360–375. doi:10.1111/j.1468-1331.2011.03501.x.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd list. 2023. Available at: WHO Essential Medicines.
- British National Formulary (BNF). Riluzole. National Institute for Health and Care Excellence (NICE). 2025.
- DrugBank. Riluzole. Available at: DrugBank DB00740.
About Our Medical Team
All content on iMedic is created and reviewed by qualified medical professionals following international evidence-based guidelines. Our editorial process ensures accuracy, currency, and clinical relevance.
Medical Content Team
Specialists in neurology, motor neuron disease, and clinical pharmacology with extensive experience in ALS management and neuroprotective therapies.
Medical Review Board
Independent panel of board-certified physicians who verify all medical claims against current evidence and international guidelines (WHO, EMA, FDA, NICE, EAN).
Editorial Standards
All content follows the GRADE evidence framework and is based on Level 1A evidence from systematic reviews and randomized controlled trials where available.
Independence
iMedic receives no pharmaceutical company funding or sponsorship. All content is editorially independent, ensuring unbiased medical information for patients and caregivers.